Targets › FTH1
6 programs from 5 companies in 6 trials: 3 Phase 4, 3 Phase 3; Hematology, Genitourinary, Neurology; next expected readout Oct 2027.
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. (UniProt, P02794)
Open in Phaseline: the race on FTH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital Los Angeles | NovaFerrum Iron replacement via polymaltose complex | FTH1 | Phase 4 | IDA - Iron Deficiency Anemia | Sep 2028 |
| Weill Medical College of Cornell University | Ferrous Sulfate Iron supplementation; elemental iron repletes iron stores and supports hemoglobin synthesi | FTH1 | Phase 4 | Chronic Kidney Insufficiency | Dec 2028 |
| Oregon Health and Science University | Iron-Dextran Complex Injection [InFed] Iron replacement therapy for iron-deficiency anemia | HMOX1, FTH1 | Phase 4 | Acute Blood Loss Anemia | – |
| Hull University Teaching Hospitals NHS Trust | Ferrous Sulfate Oral iron supplementation for iron deficiency anemia | FTH1 | Phase 3 | Peritoneal Dialysis | Oct 2027 |
| Hull University Teaching Hospitals NHS Trust | Monofer (iron isomaltoside 1000) Intravenous iron supplementation for iron deficiency anemia | FTH1 | Phase 3 | Peritoneal Dialysis | Oct 2027 |
| The George Institute | Deferoxamine Mesylate Iron chelator that reduces iron-mediated oxidative stress and secondary brain injury from | IRE1, FTH1 | Phase 3 | Intracerebral Hemorrhage | Jan 2028 |
Peritoneal Dialysis (2) IDA - Iron Deficiency Anemia (1) Chronic Kidney Insufficiency (1) Intracerebral Hemorrhage (1) Acute Blood Loss Anemia (1)
small molecule (6)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.